DDInter535 DDInter1376
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
Diazoxide {u} (Compound) palliates {v} (Disease) hypertension
Diazoxide {u} (Compound) downregulates {v} (Gene) GTPBP8
Diazoxide {u} (Compound) causes {v} (Side Effect) Anorexia
Diazoxide (Compound) resembles Chlorothiazide (Compound)
Diazoxide (Compound) binds KCNJ11 (Gene)
Diazoxide (Compound) upregulates PRKCQ (Gene)
Diazoxide (Compound) palliates hypertension (Disease)
Diazoxide (Compound) downregulates GTPBP8 (Gene)
Diazoxide (Compound) causes Anorexia (Side Effect)